These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. Jamieson DG; Parekh A; Ezekowitz MD J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203 [TBL] [Abstract][Full Text] [Related]
4. Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke. Hilkens NA; Algra A; Kappelle LJ; Bath PM; Csiba L; Rothwell PM; Greving JP; Neurology; 2018 Feb; 90(8):e683-e689. PubMed ID: 29374102 [TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists. Fintel DJ Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044 [TBL] [Abstract][Full Text] [Related]
9. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. Simmons BB; Yeo A; Fung K; ; Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455 [TBL] [Abstract][Full Text] [Related]
10. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. Guthrie R Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541 [TBL] [Abstract][Full Text] [Related]
11. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Diener HC; Sacco R; Yusuf S; ; Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887 [TBL] [Abstract][Full Text] [Related]
12. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153 [TBL] [Abstract][Full Text] [Related]
13. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Lee M; Saver JL; Hong KS; Rao NM; Wu YL; Ovbiagele B Ann Intern Med; 2013 Oct; 159(7):463-70. PubMed ID: 24081287 [TBL] [Abstract][Full Text] [Related]
14. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. Zhang Q; Wang C; Zheng M; Li Y; Li J; Zhang L; Shang X; Yan C Cerebrovasc Dis; 2015; 39(1):13-22. PubMed ID: 25547900 [TBL] [Abstract][Full Text] [Related]
15. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. Ding L; Peng B Eur J Neurol; 2018 Oct; 25(10):1276-1284. PubMed ID: 29855121 [TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741 [TBL] [Abstract][Full Text] [Related]
18. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? Diener HC Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062 [TBL] [Abstract][Full Text] [Related]
19. Aspirin plus clopidogrel Ye MB; Chen YL; Wang Q; An J; Ye F; Jing P Scand Cardiovasc J; 2019 Aug; 53(4):169-175. PubMed ID: 31112048 [No Abstract] [Full Text] [Related]
20. Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT. Skliut M; Jamieson DG Curr Cardiol Rep; 2008 Feb; 10(1):9-16. PubMed ID: 18416995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]